Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/30760
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarkia, R-
dc.contributor.authorMaccarthy, G-
dc.contributor.authorPayne, A-
dc.contributor.authorKarteris, E-
dc.contributor.authorPazoki, R-
dc.contributor.authorChatterjee, J-
dc.date.accessioned2025-02-18T16:09:32Z-
dc.date.available2025-02-18T16:09:32Z-
dc.date.issued2025-01-24-
dc.identifierORCiD: Rebecca Karkia https://orcid.org/0000-0001-7312-1397-
dc.identifierORCiD: Annette Payne https://orcid.org/0000-0002-2009-0141-
dc.identifierORCiD: Emmanouil Karteris https://orcid.org/0000-0003-3231-7267-
dc.identifierORCiD: Raha Pazoki https://orcid.org/0000-0002-5142-2348-
dc.identifierORCiD: Jayanta Chatterjee https://orcid.org/0000-0002-1770-4835-
dc.identifier751-
dc.identifier.citationKarkia, I. et al. (2025) 'The Association Between Metabolic Syndrome and the Risk of Endometrial Cancer in Pre- and Post-Menopausal Women: A UK Biobank Study', Journal of Clinical Medicine, 14 (3), 751, pp. 1 - 15. doi: 10.3390/jcm14030751.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/30760-
dc.descriptionData Availability Statement: Data can be made available upon requests made via the UK Biobank.en_US
dc.descriptionSupplementary Materials are available online at: https://www.mdpi.com/2077-0383/14/3/751#app1-jcm-14-00751 .-
dc.description.abstractBackground: Metabolic syndrome (MetS) is a syndrome that comprises central obesity, increased serum triglyceride (TG) levels, decreased serum HDL cholesterol (HDL) levels, raised blood pressure (BP), and impaired glucose regulation, including prediabetic and diabetic glycaemic levels. Recently, the association with endometrial cancer (EC) has been described but it is unclear if the risk associated with MetS is higher than the individual effect of obesity alone. This study investigates the association between MetS components and differing MetS definitions on EC risk and compares the risk of MetS with the risk posed by obesity alone. It also analyses how MetS affects the risk of EC development in the pre- and post-menopausal subgroups. Methods: A prospective cohort study was undertaken using data from the UK biobank. Multivariable Cox proportional risk models with the time to diagnosis (years) were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of MetS and its components on the risk of EC. A subgroup analysis was also undertaken for pre- and post-menopausal participants. Kaplan–Meier (KM) was undertaken to assess the difference in the risk of EC development in differing BMI classes, and in pre- and post-menopausal subgroups. Results: A total of 177,005 females from the UK biobank were included in this study. Of those participants who developed EC (n = 1454), waist circumference > 80 cm, BMI > 30 kg/m2, hypertension > 130/80 mmHg, hyperlipidaemia and diabetes (HbA1C > 48 mmol/L were significant predictors of EC development, with waist circumference being the strongest predictor (HR = 2.21; 95% CI: 1.98–2.47, p < 0.001). Comparing the pre- and post-menopausal subgroup, hypertriglyceridaemia and diabetes were the strongest predictors of EC in the pre-menopausal subgroup (HR = 1.53; 95% CI: 1.18–1.99 and HR = 1.51; 95% CI: 1.08–2.12, p < 0.05, respectively). Raised waist circumference was not a significant independent predictor in the pre-menopausal subgroup. A KM curve analysis showed a clear distinction between those with and without MetS in the pre-menopausal group, suggesting a benefit of testing for MetS components in pre-menopausal women with obesity. Conclusions: Components of MetS, both independently and in combination, significantly increase the risk of EC. Screening those with obesity for MetS in their pre-menopausal years may help to identify those at the highest risk.en_US
dc.description.sponsorshipThe funding to access the UK Biobank data was supported by the Brunel University London BRIEF AWARDS 2020/21 awarded to Raha Pazoki.en_US
dc.format.extent1 - 15-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.rightsAttribution 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectendometrial canceren_US
dc.subjectUK Biobanken_US
dc.subjectrisk stratificationen_US
dc.subjectmetabolic syndromeen_US
dc.subjectobesityen_US
dc.subjectadipokinesen_US
dc.titleThe Association Between Metabolic Syndrome and the Risk of Endometrial Cancer in Pre- and Post-Menopausal Women: A UK Biobank Studyen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/jcm14030751-
dc.relation.isPartOfJournal of Clinical Medicine-
pubs.issue3-
pubs.publication-statusPublished online-
pubs.volume14-
dc.identifier.eissn2077-0383-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dcterms.dateAccepted2025-01-10-
dc.rights.holderThe authors-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).1.55 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons